Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study

Oldenburg, Jan; Kraggerud, Sigrid Marie; Brydøy, Marianne; Cvancarova, Milada; Lothe, Ragnhild; Fosså, Sophie D.

doi:10.1186/1479-5876-5-70

Cited by 88 publications

(76 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23,24 Additionally, the minor allele of XPC Lys939Gln could be associated with higher risk of ototoxicity, although the limited number of patients included in the analysis does not permit definitive conclusions. Although a recent paper 25 has reported an association of polymorphisms in the drug metabolism gene, GSTP1, with ototoxicity in testicular cancer survivors, 25 no studies relating XPC variation with hearing impairment have been published to date. A possible explanation for our observed association could be that Lys939Gln may reduce the activity of XPC, and thus its DNA repair capacity.…”

Section: Dna Repair Gene Polymorphisms In Osteosarcoma Treatmentmentioning

confidence: 99%

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients

et al. 2009

View full text Add to dashboard Cite

Platinum agents cause DNA cross-linking. Nucleotide excision repair genes play a key role in DNA damage repair. This study aims to investigate whether polymorphisms in these genes are associated with tumor response and survival in cisplatin-treated osteosarcoma patients. Eight single nucleotide polymorphisms in ERCC2, XPC, XPA, ERCC1, ERCC4 and ERCC5 genes were analyzed in 91 patients diagnosed with osteosarcoma and treated with cisplatin. A significant association with tumor response, after correction for multiple testing, was found for the Lys751Gln polymorphism in the ERCC2 gene. We found that only 45% of patients with at least one polymorphic G allele responded compared with 80% of patients homozygous for the common T allele (odds ratio ¼ 4.9, 95% confidence interval ¼ 1.64-14.54, adjusted P-value ¼ 0.047). In addition, carrying at least one ERCC2 Lys751GlnG allele was significantly associated with shorter event-free survival (median ¼ 184 months, compared with 240 months for T T homozygotes; hazard ratio ¼ 5.76, 95% confidence interval ¼ 1.30-25.55; P-value ¼ 0.021). Although ototoxicity was only recorded in 32 patients, we found weak evidence of an association with the CC genotype of XPC Lys939Gln (P-value ¼ 0.042). This is the first pharmacogenetic study focused on osteosarcoma treatment providing evidence that polymorphic variants in DNA repair genes could be useful predictors of response to cisplatin chemotherapy in osteosarcoma patients.

show abstract

Section: Dna Repair Gene Polymorphisms In Osteosarcoma Treatmentmentioning

confidence: 99%

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients

et al. 2009

View full text Add to dashboard Cite

show abstract

“…In a study by Oldenburg et al, GSTP1 rs1965 was significantly associated with cisplatininduced ototoxicity in adult testicular cancer survivors (Table S4) 36 . However, this association did not achieve statistical significance in an extended patient cohort 37 . Rednam et al reported an opposite effect of GSTP1 rs1965 on cisplatin-induced hearing loss in a pediatric medulloblastoma cohort 42 .…”

Section: Gluthathione S-transferases (Gsts)mentioning

confidence: 97%

“…Overall, evidence regarding an effect of GSTP1 rs1695 on ototoxicity is thus inconsistent (Table S4) (+ evidence). Finally, associations with cisplatin-induced ototoxicity have also been reported for GSTM1 (Table S5) 36,37 and GSTT1 (Table S6) 39 . However, numerous other studies have not replicated these associations 15,[35][36][37][38]41,42 (+ evidence).…”

Section: Gluthathione S-transferases (Gsts)mentioning

confidence: 99%

“…Rednam et al reported an opposite effect of GSTP1 rs1965 on cisplatin-induced hearing loss in a pediatric medulloblastoma cohort 42 . Furthermore, five studies (4 pediatric, 1 adult) reported no significant association of GSTP1 with hearing loss 15,23,35,37,38 . Overall, evidence regarding an effect of GSTP1 rs1695 on ototoxicity is thus inconsistent (Table S4) (+ evidence).…”

Section: Gluthathione S-transferases (Gsts)mentioning

confidence: 99%

“…_ENREF_42Several studies have therefore examined polymorphisms in GST genes (GSTM, GSTP, GSTT) in the context of cisplatin-induced hearing loss (Tables S3-S6) 15,[35][36][37][38][39][40][41] .…”

Section: Gluthathione S-transferases (Gsts)mentioning

confidence: 99%

See 2 more Smart Citations

Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers

Lee

Pussegoda

Rassekh

et al. 2016

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

Abstract:Currently no pharmacogenomics-based criteria exist to guide clinicians in identifying individuals who are at risk of hearing loss from cisplatin-based chemotherapy. This review summarizes findings from pharmacogenomic studies that report genetic polymorphisms associated with cisplatin-induced hearing loss and aims to (1) provide up-to-date information on new developments in the field; (2) provide recommendations for the use of pharmacogenetic testing in the prevention, assessment and management of cisplatin-induced hearing loss in children and adults; and (3) identify knowledge gaps to direct and prioritize future research. These practice recommendations for pharmacogenetic testing in the context of cisplatin-induced hearing loss reflect a review and evaluation of recent literature and are designed to assist clinicians in providing optimal clinical care for patients receiving cisplatin based chemotherapy.

show abstract

Manifestations of Drug Toxicity on Mitochondria in the Nervous System

Prehn

Llorente‐Folch

2018

Mitochondrial Dysfunction Caused by Drugs and Environmental Toxicants

View full text Add to dashboard Cite

Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study

Abstract: Background: To assess the impact of polymorphisms in Glutathione S-transferase (GST) -P1, -M1, and -T1 on self-reported chemotherapy-induced long-term toxicities in testicular cancer survivors (TCSs).

Cited by 88 publications

References 40 publications

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients

Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers

Manifestations of Drug Toxicity on Mitochondria in the Nervous System

Contact Info

Product

Resources

About